Jenburkt Pharmaceuticals Reports 28% Profit Growth for FY2025-26

Jenburkt Pharmaceuticals Limited has announced its audited standalone financial results for the quarter and fiscal year ended March 31, 2026. The company demonstrated resilient performance, with annual total income rising by 13% and pre-tax profits seeing a significant jump compared to the previous fiscal year.

The results indicate a strong closing for the fourth quarter, driven by an uptick in operational revenue and a substantial increase in other income.

Annual Financial Highlights (FY26 vs. FY25)

The company's full-year performance shows steady scaling across key financial metrics:

Total Income: Climbed to ₹17,904.00 Lakhs, up from ₹15,841.25 Lakhs in the prior year.

Revenue from Operations: Contributed ₹16,874.06 Lakhs to the topline, reflecting an 11.2% growth year-on-year.

Other Income: Saw a sharp rise to ₹1,029.94 Lakhs compared to ₹672.10 Lakhs in FY25.

Total Expenses: Stood at ₹12,857.00 Lakhs. While employee benefit expenses and purchase of stock-in-trade increased, the company managed to maintain controlled finance costs at ₹46.20 Lakhs.

Profit Before Tax (PBT): Surged to ₹5,047.00 Lakhs, representing a 28.6% growth over the ₹3,925.38 Lakhs (implied) recorded in the previous year.

Quarterly Performance (Q4 FY26 vs. Q4 FY25)

The fourth quarter ending March 31, 2026, outpaced the previous year's corresponding quarter in terms of profitability:

Quarterly Revenue: Revenue from operations for Q4 stood at ₹4,463.23 Lakhs, compared to ₹4,104.69 Lakhs in Q4 FY25.

Quarterly Profitability: Profit before exceptional items and tax for the quarter reached ₹1,765.93 Lakhs, a robust increase from the ₹1,183.54 Lakhs reported in the same period last year.

Operational Shifts: The company reported a significant change in inventories (Finished Goods/WIP) of ₹(222.68) Lakhs for the quarter, indicating strong stock movement or year-end adjustments compared to a positive inventory build-up in the previous year.

Expenditure Trends

Jenburkt's expenditure profile for the year reflects its focus on market expansion and human capital:

Employee Benefits: Remained the largest expense head at ₹4,988.22 Lakhs for the year.

Stock Procurement: Purchase of stock-in-trade rose to ₹2,817.89 Lakhs, signaling an expansion in the company's distributed product portfolio.

Other Expenses: Including marketing and administrative costs, these rose to ₹4,279.25 Lakhs for the full year.

The significant growth in "Other Income" and the 28% jump in annual profit suggest that Jenburkt Pharmaceuticals has successfully optimized its non-core revenue streams while maintaining steady growth in its pharmaceutical operations. With a healthy pre-tax profit exceeding ₹50 Crore (₹5,047 Lakhs), the Mumbai-based firm enters the 2026-27 fiscal year with a strengthened balance sheet and improved operational margins.

Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 1074.50 as compared to the previous close of Rs. 1042.20. The total number of shares traded during the day was 2492 in over 206 trades.

The stock hit an intraday high of Rs. 1119.20 and intraday low of 1057.00. The net turnover during the day was Rs. 2716047.00.

Source : Equity Bulls

Keywords

JENBURKTPHARMACEUTICALS INE354A01013 Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate